'It's rare and it's scary.' Dark spot on your fingernail could mean cancer

New research published earlier this month in AIDS and Behavior highlights links between extreme weather events, such as drought and flooding, and increased HIV vulnerabilities among sex workers and sexually diverse men in Nairobi, Kenya.

For gene therapy to work well, therapeutic molecules need to be efficiently delivered to the correct locations in the body—a job commonly given to adeno-associated viruses (AAV).

In February this year, the U.S. Food and Drug Administration and U.S. Customs and Border Protection seized nearly 2 million units of unauthorized electronic cigarette products in Chicago.

Childhood cancer survivors (CCS) have an increased risk of chronic kidney disease (CKD) and hypertension, according to a study published online May 19 in JAMA Network Open.

For patients with amyotrophic lateral sclerosis (ALS), rapid eye movement (REM) inhibition via receipt of antidepressant medication is associated with a trend toward survival benefit, according to a study presented at the American Thoracic Society 2025 International Conference, held from May 18 to 21 in San Francisco.

Just over half of youth-serving clinicians report that they routinely screen adolescents for substance-use disorders (SUDs) at every well visit, according to a study published online May 20 in JAMA Network Open.

When a physician says a procedure is "rarely risky," what does that really mean? Although terms like "common" and "unlikely" may sound descriptive enough, experts in medical decision-making suggest that leaving out numbers may be misleading for patients.

Clinical trials are a crucial step in medical research, and without adequate numbers of participants, treatments can be delayed or prevented from reaching the health care market.

A grid of electrodes placed on the backs of study participants delivered enough low-voltage electrical stimulation through the skin to change the short-term function of spinal cord neurons, a study led by UT Southwestern Medical Center researchers showed.

On the last day of patient care at the Planned Parenthood clinic in Marquette, Michigan, a port town on the shore of Lake Superior, dozens of people crowded into the parking lot and alley, holding pink homemade signs that read "Thank You!" and "Forever Grateful."

Australian nurses have responded to hundreds of disaster events over the last six years, but new research led by Charles Darwin University (CDU) suggests they still aren't ready for the impact of catastrophe. The work is published in the journal Health Emergency and Disaster Nursing.

Grassroots rugby concussion guidelines need to be improved as players' brains remain altered despite them being symptom-free and cleared to play, researchers have found.

In the early months of 2020, a curious thing happened. Around the globe, a new kind of number began appearing in government briefings and newspaper headlines. These weren't just case counts or hospital admissions. They were predictions—curves plotted weeks into the future, graphs that told us when the COVID-19 wave would crest, how many ICU beds we'd need, and how soon we'd be safe again. The models had arrived.

People who have been taking antidepressants for more than two years are substantially more likely to experience withdrawal symptoms compared to short-term users when they come off the medication, finds a new study led by UCL researchers.

There is a strong association between an older person's view of how they are aging and how well they will physically recover after a fall.

Scientists in the U.K., Australia and China have identified a brain molecule called NEAT1 that appears to play a central role in triggering light sensitivity (photophobia), a common and debilitating symptom of migraines. Their findings, published in The Journal of Headache and Pain, highlight how this molecule affects the brain's pain response, contributing to the uncomfortable reaction to light that's common during migraines.

For patients with diffuse gliomas, tumor-related epilepsy (TRE) is not a strong prognostic factor, according to a study published in the May issue of Brain and Behavior.

The U.S. Food and Drug Administration has approved the humanized monoclonal antibody Zynyz (retifanlimab-dlwr) as the first first-line treatment for advanced anal cancer.